Compass Pathways Launches First U.S. TRD Awareness Day with Mental Health Advocates

  • Compass Pathways (Nasdaq: CMPS) initiated the first U.S. Treatment-Resistant Depression (TRD) Awareness Day on October 14, 2026, in collaboration with leading mental health organizations.
  • TRD affects approximately 4 million people in the U.S., with fewer than 5% currently on TRD-indicated treatment.
  • A new survey found 95% of TRD patients describe themselves as struggling or barely getting by, with 66% of caregivers reporting significant mental health tolls.
  • Compass Pathways is developing COMP360 psilocybin, a proprietary synthetic psilocybin treatment for TRD, with Breakthrough Therapy designation from the FDA.

Compass Pathways' TRD Awareness Day underscores the growing recognition of treatment-resistant depression as a distinct and underserved condition within mental health care. The collaboration with major advocacy groups highlights the strategic importance of patient-centric approaches in advancing biotech solutions for high-unmet-need indications. The initiative comes as Compass Pathways continues to lead the world's largest classic psychedelic clinical program, positioning itself at the forefront of a potential paradigm shift in psychiatric treatment.

Regulatory Progress
The pace at which COMP360 psilocybin advances through clinical trials and secures regulatory approvals for TRD and PTSD.
Market Adoption
Whether Compass Pathways can sustain momentum in raising awareness and securing partnerships to drive adoption of TRD treatments.
Patient Outcomes
How early recognition and treatment of TRD through awareness initiatives impact patient outcomes and caregiver burden.